Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - BriaCell Therapeutics Corp.

Ratings ESG MSCI

Ratings ESG MSCI - BriaCell Therapeutics Corp.

Ratings BriaCell Therapeutics Corp.: Strengths and Weaknesses

Rating Financials

BriaCell Therapeutics Corp. SectorUnited States

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings
Fundamental Rankings - BriaCell Therapeutics Corp.

Rating Valuation

BriaCell Therapeutics Corp. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings
Fundamental Rankings - BriaCell Therapeutics Corp.

Rating Consensus

BriaCell Therapeutics Corp. SectorUnited States

Consensus

-

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

-

Analysts' target price evolution (1 year)

-

Analysts' target price evolution (4 months)

-

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

-
More ratings
Fundamental Rankings - BriaCell Therapeutics Corp.

Rating Business Predictability

BriaCell Therapeutics Corp. SectorUnited States

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Fundamental Rankings - BriaCell Therapeutics Corp.

Rating Revisions

BriaCell Therapeutics Corp. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - BriaCell Therapeutics Corp.


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
33.97M - - - - - -
72.13B
AAA
49.41B
A
47.24B
AAA
40.32B -
B
- -
42.61B
AAA
39.81B -
30.52B
A
23.13B - - - -
21.09B
A
Average 36.63B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. BCT Stock
  4. BCTX Stock
  5. Ratings BriaCell Therapeutics Corp.